Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(7-carbamimidoyl-naphthalen-1-yl)-3-hydroxy-2-methyl-benzamide is an experimental small molecule compound belonging to the class of naphthalene derivatives. It has been structurally characterized and is known to bind to coagulation factor XI (FXI), a serine protease involved in the intrinsic pathway of blood coagulation. Structural studies have shown this compound as a ligand in complex with the catalytic domain of human factor XI, suggesting its role as an inhibitor of this target[6]. The primary research interest for this molecule is as a potential anticoagulant through inhibition of factor XIa activity. There are no approved indications or clinical development programs reported for this compound; it remains at the experimental stage[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(7-carbamimidoyl-naphthalen-1-yl)-3-hydroxy-2-methyl-benzamide.